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Introduction
Amyotrophic lateral sclerosis (ALS, also known as motor neuron disease, MND) is a fatal neurodegenerative disease that is characterised by the rapidly progressive degeneration of the upper and lower motor neurons. The progression of paralysis is profound, rapidly leading to death, usually from respiratory failure within 2 to 5 years of first symptoms. To date the only known cause of ALS are gene mutations, which have been reported in more than 20 genes (ALS Online Database (ALSoD 6.0 at http://alsod.iop.kcl.ac.uk) (Abel, et al., 2013) and reviewed in Renton, et al. (2014) ).
Much of our understanding of disease pathology has stemmed from genetic discoveries in the hereditary form of the disease (familial ALS). Gene discovery in ALS has long comprised of multi-generational pedigree analyses using exome sequencing and/or linkage analysis to identify causative mutations. More recently, gene discovery strategies in ALS have included statistical genetic analyses of large cohorts of probands, including both familial and sporadic cases.
The TANK-binding kinase 1 (TBK1) gene was recently reported as an ALS gene through rare variant enrichment analyses (Cirulli, et al., 2015) and familial discovery studies (Freischmidt, et al., 2015) . Several ALS-linked mutations have been identified in this gene, predominantly insertions/deletions that result in frameshift mutations and truncated proteins. Cirulli, et al. (2015) used whole exome sequence data from a large cohort of ALS patients (both familial and sporadic cases) and controls to observe for enrichment of genetic-model-specific variants in patients.
They used a gene-based collapsing analysis across six genetic models including dominant coding, recessive coding, dominant not benign, recessive not benign, dominant loss of function, and recessive loss of function. Using a discovery dataset of 2843 cases and 4310 controls, 51 genes (including TBK1) showed association M A N U S C R I P T A C C E P T E D Several of the families with TBK1 loss of function variants described in this study have comorbid ALS and/or frontotemporal dementia (FTD)/cognitive impairment.
Further functional analysis suggested that haploinsufficiency is the most likely pathogenic mechanism underlying these loss of function variants. Since Freischmidt, et al. (2015) identified TBK1 mutations in 4% of genetically unexplained FALS, they suggested that TBK1 mutations may be a common genetic cause among Caucasians with ALS.
To determine the overall contribution of this particular gene to ALS across multiple ethnicities, mutation screening in extended geographical cohorts is required.
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We have examined TBK1 variants in a cohort of Australian familial ALS cases and identified a previously unreported single base pair deletion, resulting in a frameshift mutation, in an Australian patient of Chinese origin. The patient had limb onset and developed cognitive impairment with language disturbance, however they were not formally diagnosed with FTD. As all previous ALS-linked TBK1 mutations have been identified in European cases, this is the first report of a TBK1 mutation in an ALS patient of non-European origin. No novel TBK1 variants were identified in ALS patients of European background.
Material and methods
Participants
We analysed a total of 127 individuals from 94 Australian ALS families. Freischmidt, et al. (2015) reported segregation of loss of function TBK1 variant and a pathogenic FUS missense variant in a single patient, therefore we included 39 patients who were positive for a mutation in a known ALS gene to prevent omitting possible oligogenic cases (van Blitterswijk, et al., 2012) . The remaining 88 patients (from 75 families) were negative for known ALS genes. It should be noted that 89/127 cases, excluding the discovery case described here, are part of the FALS sequencing consortium described in Cirulli, et al. (2015) . Samples were recruited from Molecular Medicine Laboratory at Concord Hospital, the Australian MND DNA bank and from the Macquarie University MND Biobank. Patients, family members and unrelated controls were recruited under informed written consent as approved by the institutional review boards of the participating institutions. Patients were diagnosed with definite or probable ALS according to El Escorial criteria (Brooks, et al., 2000) .
Patients had previously been screened for mutations/expansions in known ALS M A N U S C R I P T A C C E P T E D 
Results
Identification of a novel TBK1 frameshift mutation
We examined whole exome sequence data from familial ALS patients and controls to determine the frequency of TBK1 mutations in Australian familial ALS. Exome sequencing achieved a mean read depth of >60X across all TBK1 coding exons. We identified an unreported frameshift mutation in TBK1 (c.1197delC, p.L399fs) in an Australian ALS patient of Chinese origin (Fig. 1B) . The mutation is absent from all public SNP databases including dbSNP141, the 1000 Genomes Project, the NHLBI Exome Sequencing Project (ESP) exome variant server and Exome Aggregation Consortium (ExAC) and the Diamantina Control Cohort. The frameshift deletion is predicted to result in a truncated protein of 407 amino acids (Fig. 1C) . No DNA was available from other family members. No tissue was available to assess transcription of the mutant allele. Bioinformatic analysis using MutationTaster (Schwarz, et al., 2014) and SIFT version 5.2.2 (Kumar, et al., 2009) clinical information is available on these control subjects).
Clinical presentation of the TBK1 frameshift mutation family
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The proband (III:1; Fig. 1A ) is from a three-generation family of Chinese origin in which the proband and his mother had ALS and two maternal uncles and maternal grandfather have historical diagnoses of Parkinson's Disease (Fig. 1A) . The proband had a long standing history of bronchiectasis secondary to pneumonia as a child. He also had a six-year history of mild depression, and a two-year history of complex partial seizures controlled with carbemazepine. At age 60 he developed progressive right arm weakness and, after two years, was referred to a neurologist. At 
Discussion
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Here we describe a novel TBK1 truncating mutation in an Australian familial ALS patient of Chinese origin. The normal TBK1 protein comprises 729 amino acids and this frameshift mutation truncates the protein by 44% to 407 amino acids. The truncated protein retains the N-terminal kinase domain (KD) and the ubiquitin-like domain (ULD) however lacks the entire α-helical scaffold and dimerization domain (SDD) and the C-terminal domain (Fig. 1C) (Larabi, et al., 2013 ,Tu, et al., 2013 . As such, structural integrity of the protein and its adapter protein binding may be hindered.
Normal TBK1 functions as a dimer through extensive hydrophobic contact between the ULD and SDD (Larabi, et al., 2013 ,Tu, et al., 2013 . However since the truncated protein does not contain the SDD, it is unlikely to form this native dimer conformation and would thereby remain inactive.
Activation of TBK1 requires polyubiquitination of amino acids K30 and K401 (Tu, et al., 2013) . Interestingly, one of the missense variants (p.K401E) identified in the Diamantina control cohort is located at one of these polyubiquitination sites, with unknown consequence. This rare variant was also present in a public SNP database.
A major functional consequence of the described frameshift mutation would be impairment of TBK1 binding to the adapter proteins TANK, NAP1, SINTBAD, and optineurin (coded by OPTN) (Larabi, et al., 2013) . The C-terminal domain structurally extends away from the KD-ULD-SDD dimer complex (Larabi, et al., 2013) and binds to the adapter proteins (Goncalves, et al., 2011) . Immunoprecipitation and GST pulldown assay experiments performed by Freischmidt, et al. (2015) showed that mutations in the C-terminal domain render TBK1 unable to bind optineurin. Cirulli, et al. (2015) and Freischmidt, et al. (2015) identified multiple truncation and missense mutations scattered throughout the entire TBK1 protein, in all four M A N U S C R I P T
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11 functional domains. Cirulli, et al. (2015) identified 11 loss of function mutations in ALS patients, with most falling within the SDD, and the remainder upstream of the SDD. Seven of the eight TBK1 loss of function mutations identified in familial ALS patients by Freischmidt, et al. (2015) also lie within or upstream of the SDD.
Similarly, the p.L399fs frameshift mutation described here lies upstream of the SDD, providing additional evidence for its pathogenic role.
Haploinsufficiency of TBK1 has been shown to lead to ALS and FTD (Cirulli, et al., 2015 , Freischmidt, et al., 2015 , while duplication of TBK1 results in overexpression of TBK1 leading to normal tension glaucoma, a neurodegenerative disorder involving the optic nerve (Kawase, et al., 2012) . This suggests that TBK1 gene dosage is critical for normal function. Previously reported data from patient cell lines showed no expression of the mutant TBK1 alleles at the mRNA or protein level for all loss of function mutations that fall within or upstream of the SDD (Freischmidt, et al., 2015) . As such, the mutation described here would likely also lead to dosage effects through the generation of a non-functional protein or via nonsense mediated decay.
Normal tension glaucoma caused by TBK1 duplication (Shields, 2008 ) is part of a continuum of optic nerve neurodegenerative disorders with primary open-angle glaucoma (Shields, 2008) caused by mutations in OPTN (Rezaie, et al., 2002) .
Missense and nonsense mutations in OPTN have also been identified in familial and sporadic ALS cases (Maruyama, et al., 2010) .
The discovery family in this study presented with ALS and Parkinson's disease (Fig. 1A) . Unfortunately no DNA or tissue was available from any of these patients to determine whether they also harboured the TBK1 p.L399fs mutation. The two neurodegenerative phenotypes seen in this family, coupled with TBK1 duplications found in normal tension glaucoma (Kawase, et al., 2012) and TBK1 mutations in FTD patients (Freischmidt, et al., 2015) Sequence chromatograms showing the two alleles, the resultant amino acids for this section of protein and the premature stop codon in the mutant allele. C.
Diagrammatic representation of wildtype TBK1 and the predicted truncated protein.
Functional domains include N-terminal kinase domain (KD), the ubiquitin-like domain (ULD), α-helical scaffold and dimerization domain (SDD) and the C-terminal domain (CTD) (Larabi, et al., 2013 ,Tu, et al., 2013 . • This is the first report of a TBK1 mutation in an ALS patient of Asian origin
• TBK1 mutations are a rare cause of ALS in Australia
